Hence, PRMT5-mediated D2R arginine methylation may upregulate D2R signaling either by directly affecting the interaction site of the receptor with G proteins and subsequently its activity or indirectly by altering its interaction with other regulatory binding proteins, thereby regulating dopaminergic neurotransmission with potential implications in PD pathophysiology and pharmacotherapy, which should be further investigated. The gene discussed is DRD2; the disease is Parkinson disease.